Becton, Dickinson and Company, known as BD, is a global medical technology company listed on the NYSE under the symbol BDX. BD specializes in the development and sale of medical devices, instrument systems, and reagents. The company competes with other major players in the healthcare sector, focusing on innovation and enhancing shareholder value.
On February 9, 2026, BD reported earnings per share (EPS) of $2.91, surpassing the estimated $2.82. This achievement reflects the company's strong financial performance, as highlighted by its fiscal 2026 first-quarter results. BD's revenue increased by 1.6% to $5.3 billion, exceeding the estimated $5.15 billion. On a foreign exchange-neutral basis, revenue rose by 0.4%, while the new BD revenue saw a 2.5% increase.
BD's strategic initiatives are evident in its recent merger with Waters Corporation, combining its Biosciences and Diagnostic Solutions business. This move aims to enhance shareholder value by focusing on commercial capabilities, innovation, and productivity. The merger is expected to contribute to gross margin expansion, aligning with BD's long-term growth strategy.
Tom Polen, BD's chairman, CEO, and president, expressed satisfaction with the company's performance, attributing it to disciplined execution and accelerated commercial initiatives. BD has affirmed its fiscal year 2026 revenue growth guidance and provided adjusted diluted EPS guidance for the new BD, indicating confidence in its future prospects.
BD's financial metrics provide insight into its market position. With a price-to-earnings (P/E) ratio of approximately 35.87, investors are willing to pay a premium for each dollar of earnings. The company's price-to-sales ratio of about 2.74 and enterprise value to sales ratio of 3.58 reflect the value placed on its sales. Additionally, BD's debt-to-equity ratio of approximately 0.76 indicates a balanced approach to financing its assets.
